We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$148M
AUM Growth
+$35.6M
Cap. Flow
+$28.1M
Cap. Flow %
18.99%
Top 10 Hldgs %
35.62%
Holding
82
New
30
Increased
14
Reduced
8
Closed
23

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$4.65M
2
ALGN icon
Align Technology
ALGN
+$4.41M
3
GERN icon
Geron
GERN
+$4.12M
4
GILD icon
Gilead Sciences
GILD
+$3.82M
5
SWTX
SpringWorks Therapeutics
SWTX
+$3.76M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$5.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$3.84M
3
TVTX icon
Travere Therapeutics
TVTX
+$3.64M
4
ONC
BeOne Medicines Ltd
ONC
+$3.22M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
2 Financials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMT icon
76
Sagimet Biosciences
SGMT
$439M
– –
-50,700
Closed -$173K
SRPT icon
77
Sarepta Therapeutics
SRPT
$1.57B
– –
-32,900
Closed -$5.2M
TVTX icon
78
Travere Therapeutics
TVTX
$5.2B
– –
-443,379
Closed -$3.64M
WVE icon
79
Wave Life Sciences
WVE
$1.09B
– –
-488,135
Closed -$2.44M
ZLAB icon
80
Zai Lab
ZLAB
$2.06B
– –
-86,700
Closed -$1.5M
QTTB icon
81
Q32 Bio
QTTB
$466M
– –
-43,865
Closed -$787K
1 2 3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Exome Asset Management held 82 positions worth $148M, up 32% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Exome Asset Management deployed $28.1M of net new capital in Q3 2024, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was Structure Therapeutics: 120,165 shares worth $5.27M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $3.22M trimmed.

  • Exome Asset Management's largest Q3 2024 buy was Structure Therapeutics: 120,165 shares worth $5.27M.
  • Exome Asset Management added most to BridgeBio Pharma in Q3 2024, an estimated $3.47M increase.
  • Exome Asset Management's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $3.22M.
  • Exome Asset Management fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $5.2M.
  • Exome Asset Management's ten largest holdings make up 36% of its $148M portfolio in Q3 2024.
  • Exome Asset Management opened 30 new positions and closed 23 in Q3 2024.
  • Exome Asset Management's portfolio value rose 32% quarter-over-quarter to $148M.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.